Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Mar 21

PMID 35311145

Authors

Duoli Xie

Zhuqian Wang

Jie Li

De-An Guo

Aiping Lu

Chao Liang

Affiliations

Soon will be listed here.

Abstract

Since osteosarcoma (OS) is an aggressive bone cancer with unknown molecular pathways of etiology and pathophysiology, improving patient survival has long been a challenge. The conventional therapy is a complex multidisciplinary management that include radiotherapy, chemotherapy which followed by surgery and then post-operative adjuvant chemotherapy. However, they have severe side effects because the majority of the medicines used have just a minor selectivity for malignant tissue. As a result, treating tumor cells specifically without damaging healthy tissue is currently a primary goal in OS therapy. The coupling of chemotherapeutic drugs with targeting ligands is a unique therapy method for OS that, by active targeting, can overcome the aforementioned hurdles. This review focuses on advances in ligands and chemotherapeutic agents employed in targeted delivery to improve the capacity of active targeting and provide some insight into future therapeutic research for OS.

Citing Articles

The homeobox family gene signature predicts the prognosis of osteosarcoma and correlates with immune invasion.

Liu W, Xia K, Huang X, Wei Z, Wei Z, Guo W Sci Rep. 2025; 15(1):886.

PMID: 39762460 PMC: 11704140. DOI: 10.1038/s41598-024-84924-w.

Recurrent Osteosarcoma Presenting as Hepatic Metastasis: A Case Report.

Imran A, Naeem M, Fatima N, Muneer K, Siddique K Cureus. 2024; 16(11):e73087.

PMID: 39650980 PMC: 11624013. DOI: 10.7759/cureus.73087.

Nanoarchitectonics of copper sulfide nanoplating for improvement of computed tomography efficacy of bismuth oxide constructs toward drugless theranostics.

Meng R, Xia H, Zhao Y, Ye Y, Wang S, Chen A Regen Biomater. 2024; 11:rbae128.

PMID: 39600909 PMC: 11593496. DOI: 10.1093/rb/rbae128.

Role of proteoglycan synthesis genes in osteosarcoma stem cells.

Osumi R, Sugihara K, Yoshimoto M, Tokumura K, Tanaka Y, Hinoi E Front Oncol. 2024; 14:1325794.

PMID: 38690160 PMC: 11058990. DOI: 10.3389/fonc.2024.1325794.

Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates.

Schoffski P, Wang C, Schoffski M, Wozniak A Oncol Res Treat. 2023; 47(1-2):18-41.

PMID: 38016427 PMC: 10860894. DOI: 10.1159/000535491.

References

Ai J, Liu B, Liu W . Folic acid-tagged titanium dioxide nanoparticles for enhanced anticancer effect in osteosarcoma cells. Mater Sci Eng C Mater Biol Appl. 2017; 76:1181-1187. DOI: 10.1016/j.msec.2017.03.027. View

Zhao L, Bi D, Qi X, Guo Y, Yue F, Wang X . Polydopamine-based surface modification of paclitaxel nanoparticles for osteosarcoma targeted therapy. Nanotechnology. 2019; 30(25):255101. DOI: 10.1088/1361-6528/ab055f. View

Cui J, Dean D, Wei R, Hornicek F, Ulmert D, Duan Z . Expression and clinical implications of leucine-rich repeat containing 15 (LRRC15) in osteosarcoma. J Orthop Res. 2020; 38(11):2362-2372. DOI: 10.1002/jor.24848. View

Erak M, Bellmann-Sickert K, Els-Heindl S, Beck-Sickinger A . Peptide chemistry toolbox - Transforming natural peptides into peptide therapeutics. Bioorg Med Chem. 2018; 26(10):2759-2765. DOI: 10.1016/j.bmc.2018.01.012. View

Liu T, Yan Z, Liu Y, Choy E, Hornicek F, Mankin H . CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells. Cell Physiol Biochem. 2018; 46(3):1218-1230. DOI: 10.1159/000489072. View

Isakoff M, Bielack S, Meltzer P, Gorlick R . Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015; 33(27):3029-35. PMC: 4979196. DOI: 10.1200/JCO.2014.59.4895. View

Firer M, Gellerman G . Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol. 2012; 5:70. PMC: 3508879. DOI: 10.1186/1756-8722-5-70. View

Chau C, Steeg P, Figg W . Antibody-drug conjugates for cancer. Lancet. 2019; 394(10200):793-804. DOI: 10.1016/S0140-6736(19)31774-X. View

Kovach A, Gambino J, Nguyen V, Nelson Z, Szasz T, Liao J . Prospective Preliminary Investigation of a Magnetic Iron Oxide Nanoparticle Conjugated with Ligand CD80 and VEGF Antibody As a Targeted Drug Delivery System for the Induction of Cell Death in Rodent Osteosarcoma Cells. Biores Open Access. 2016; 5(1):299-307. PMC: 5107667. DOI: 10.1089/biores.2016.0020. View

10.

Rotman S, Grijpma D, Richards R, Moriarty T, Eglin D, Guillaume O . Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics. J Control Release. 2017; 269:88-99. DOI: 10.1016/j.jconrel.2017.11.009. View

11.

Polito L, Calafato G, Bortolotti M, Chiarelli Olivari C, Maiello S, Bolognesi A . Antibody Conjugates for Sarcoma Therapy: How Far along Are We?. Biomedicines. 2021; 9(8). PMC: 8392509. DOI: 10.3390/biomedicines9080978. View

12.

Wolska-Washer A, Robak T . Safety and Tolerability of Antibody-Drug Conjugates in Cancer. Drug Saf. 2019; 42(2):295-314. PMC: 6399172. DOI: 10.1007/s40264-018-0775-7. View

13.

Eliaz R, Nir S, Marty C, Szoka Jr F . Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res. 2004; 64(2):711-8. DOI: 10.1158/0008-5472.can-03-0654. View

14.

Liu Y, Zhang F, Zhang Z, Wang D, Cui B, Zeng F . High expression levels of Cyr61 and VEGF are associated with poor prognosis in osteosarcoma. Pathol Res Pract. 2017; 213(8):895-899. DOI: 10.1016/j.prp.2017.06.004. View

15.

Hingorani P, Roth M, Wang Y, Zhang W, Gill J, Harrison D . ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium. Mol Cancer Ther. 2020; 20(3):535-540. PMC: 8715742. DOI: 10.1158/1535-7163.MCT-20-0406. View

16.

Sun H, Zu Y . Aptamers and their applications in nanomedicine. Small. 2015; 11(20):2352-64. PMC: 4441590. DOI: 10.1002/smll.201403073. View

17.

Haghiralsadat F, Amoabediny G, Naderinezhad S, Nazmi K, Posthuma DE Boer J, Zandieh-Doulabi B . EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment. Pharm Res. 2017; 34(12):2891-2900. DOI: 10.1007/s11095-017-2272-6. View

18.

Zitzmann S, Ehemann V, Schwab M . Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 2002; 62(18):5139-43. View

19.

Hock M, Thudium K, Carrasco-Triguero M, Schwabe N . Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. AAPS J. 2014; 17(1):35-43. PMC: 4287284. DOI: 10.1208/s12248-014-9684-6. View

20.

Mukherjee A, Waters A, Babic I, Nurmemmedov E, Glassy M, Kesari S . Antibody drug conjugates: Progress, pitfalls, and promises. Hum Antibodies. 2018; 27(1):53-62. DOI: 10.3233/HAB-180348. View